MMP2 and non-small cell lung carcinoma: The proteasome inhibitor bortezomib in combination with the histone deacetylase inhibitor romidepsin inhibited the expression of MMP-2 and MMP-9 in A549 non-small-cell lung cancer (NSCLC) cells (48).